HGH 191AA is a recombinant human growth hormone identical to naturally occurring GH. It is typically dosed via subcutaneous injection to improve body composition and metabolic function. Protocols often involve a gradual increase in dosage over several weeks.
- Structurally identical to endogenous human growth hormone.
- Administered subcutaneously, typically at bedtime.
- Promotes lean body mass and reduces adipose tissue.
- Dose titration commonly used to manage effects.
- Rotate injection sites to prevent local irritation.
Reconstitution
Vial strength
3.33 mg
Bacteriostatic water
3 mL
Concentration
1.11 mg/mL
1 unit = 0.01 mL = 11.1 mcg
- 1Draw 3.0 mL of bacteriostatic water using a sterile syringe.
- 2Inject the water slowly down the inside wall of the HGH 191AA vial to prevent foaming.
- 3Gently swirl or roll the vial until the powder is fully dissolved; do not shake vigorously to protect the peptide's structure.
- 4Label the reconstituted vial with the date and refrigerate it at 2–8 °C (35.6–46.4 °F), protected from light.
Dosing schedule
| Phase | Dose | On a U-100 syringe |
|---|---|---|
| Week 1 | 200 mcg | 18 units (0.18 mL) |
| Week 2 | 300 mcg | 27 units (0.27 mL) |
| Week 3 | 400 mcg | 36 units (0.36 mL) |
| Week 4 | 500 mcg | 45 units (0.45 mL) |
| Week 5 | 600 mcg | 54 units (0.54 mL) |
| Week 6 | 700 mcg | 63 units (0.63 mL) |
| Week 7 | 800 mcg | 72 units (0.72 mL) |
| Week 8 | 900 mcg | 81 units (0.81 mL) |
Protocol detail
| Start | Begin with 200 mcg daily, gradually increasing by approximately 100 mcg each week as tolerated. |
|---|---|
| Conservative Target | Aim for 400–900 mcg daily by Weeks 4–8. |
| Advanced Target | Reach 1000–1300 mcg daily by Weeks 9–12 for performance and metabolic research. |
| Frequency | Administer once daily via subcutaneous injection, ideally at bedtime. |
| Cycle Length | Standard 8–12 weeks, with an optional extension to 16 weeks under careful monitoring. |
| Timing | Evening or bedtime administration is preferred; consistently rotate injection sites. |
Overview at a glance
| Goal | Support increases in lean body mass, reductions in fat tissue, and enhanced metabolic function. |
|---|---|
| Schedule | Daily subcutaneous injections for 8–12 weeks; can be extended to 16 weeks for advanced protocols. |
| Dose Range | Conservative: 150–500 mcg daily; Advanced: 1000–2000 mcg daily. |
| Reconstitution | 3.0 mL bacteriostatic water per 3.33 mg vial (~1.11 mg/mL) for precise unit measurements. |
| Storage | Lyophilized frozen; reconstituted refrigerated. Avoid repeated freezing and thawing. |
How it works
HGH 191AA is a recombinant human growth hormone structurally identical to the GH naturally produced by the pituitary gland. It functions by promoting an increase in lean body mass, a reduction in fat tissue, and overall improvements in body composition. These effects are mediated through mechanisms such as enhanced fat breakdown, increased protein synthesis, and the stimulation of IGF-1 production. Administering it subcutaneously once daily, particularly before sleep, aims to mimic the body's natural pulsatile GH secretion patterns. Higher doses tend to produce more pronounced physiological effects, but also carry an increased potential for side effects.
Reported effects
- Increases lean body mass
- Reduces adipose tissue
- Enhances fat oxidation and lipolysis
- Improves muscle strength (in GH-deficient adults)
- May improve metabolic parameters
Reported side effects
- Injection site reactions (redness, irritation)
- Fluid retention and peripheral edema
- Joint discomfort or pain (arthralgias)
- Potential effects on glucose metabolism
- Risk of lipoatrophy if injection sites not rotated
Storage
Lyophilised (unmixed)
Freeze at -20 °C (-4 °F) in dry, dark conditions; minimize moisture exposure.
After reconstitution
Refrigerate at 2-8 °C (35.6-46.4 °F); stable for several weeks. Avoid freeze-thaw cycles.
Supplies
| Peptide vials | 10 IU / 3.33 mg each: 10 vials for 8 weeks, 19 vials for 12 weeks, 32 vials for 16 weeks |
|---|---|
| Insulin Syringes (U-100) | 56 for 8 weeks, 84 for 12 weeks, 112 for 16 weeks |
| Bacteriostatic Water (10 mL bottles) | 3 for 8 weeks, 6 for 12 weeks, 10 for 16 weeks |
| Alcohol Swabs | 2 boxes of 100-count for 8-12 weeks, 3 boxes for 16 weeks |
Important notes
- Always use a new, sterile insulin syringe for each injection and dispose of it in a sharps container.
- Systematically rotate injection sites (abdomen, thighs, upper arms) to prevent local irritation and lipoatrophy.
- Inject slowly and wait a few seconds before withdrawing the needle to minimize leakage.
- Document your daily dose, injection site, and any observed effects for consistency and to track tolerance.
- This content is for educational purposes only and is not medical advice; HGH 191AA is a research peptide.
Frequently asked questions
What is the primary benefit of using HGH 191AA?
HGH 191AA is primarily studied for its ability to improve body composition by increasing lean muscle mass and reducing body fat, along with enhancing metabolic function.
Why is it recommended to inject HGH 191AA at bedtime?
Injecting HGH 191AA at bedtime is suggested because it mimics the body's natural production of growth hormone, which typically peaks during sleep, potentially optimizing its effects.
What is the importance of rotating injection sites?
Rotating injection sites is crucial to prevent common issues like localized irritation, redness, and a condition called lipoatrophy, where fat tissue can waste away at a frequently used injection site.
Can HGH 191AA be used for strength gain?
While HGH 191AA increases lean body mass, systematic reviews in healthy athletes have not shown a significant improvement in muscle strength or exercise performance, although long-term use in GH-deficient adults has demonstrated sustained improvements in muscle strength.
Educational reference only. These figures summarise how HGH 191AA is commonly described in research literature and supplier documentation, including the HGH 191AA listing at peptidesuk4u.co.uk. They are not a prescription, not medical advice, and not a recommendation to self-administer anything.
Related protocols
AOD-9604 + CJC-1295 + Ipamorelin (12 mg Blend)
A powerful blend for synergistic fat loss and growth hormone optimization.
CJC-1295 DAC (2 mg Vial)
Long-acting GHRH analog for sustained growth hormone release.
GHRP-6 (10 mg Vial)
Mimics ghrelin to stimulate growth hormone release.
GHRP-6 (2 mg Vial)
Stimulates GH release for muscle growth, fat loss, and recovery.